目的 探討清濁祛毒丸聯(lián)合環(huán)丙沙星治療慢性前列腺炎的臨床療效。方法 選取2018年7月—2020年8月在鄭州市第一人民醫(yī)院進(jìn)行治療的106例慢性前列腺炎患者，根據(jù)住院號(hào)的奇偶數(shù)將所有患者分為對(duì)照組（53例）和治療組（53例）。對(duì)照組口服鹽酸環(huán)丙沙星片，0.25 g/次，2次/d；治療組在對(duì)照組基礎(chǔ)上口服清濁祛毒丸，8.0 g/次，3次/d。兩組均治療4周后進(jìn)行效果比較。觀察兩組相關(guān)評(píng)分、尿流速、血清學(xué)指標(biāo)和前列腺液相關(guān)指標(biāo)的變化情況。結(jié)果 經(jīng)治療，治療組總有效率是96.23%，顯著高于對(duì)照組的81.13%（P<0.05）。經(jīng)治療，兩組NIH-CPSI評(píng)分均較治療前顯著減低，而IIEF-5評(píng)分、EQS評(píng)分均顯著增高（P<0.05）；治療后，治療組NIH-CPSI評(píng)分低于對(duì)照組，而IIEF-5評(píng)分、EQS評(píng)分高于對(duì)照組（P<0.05）。經(jīng)治療，兩組患者最大尿流率（MFR）、平均尿流率（AFR）均明顯增高（P<0.05）；治療后，治療組MFR、AFR高于對(duì)照組（P<0.05）。經(jīng)治療，兩組血清白細(xì)胞介素-1β（IL-1β）、白細(xì)胞介素-6（IL-6）、巨噬細(xì)胞炎性蛋白-2（MIP-2）、腫瘤壞死因子-α（TNF-α）、巨噬細(xì)胞集落刺激因子（M-CSF）均較治療前顯著下降（P<0.05）；治療后，治療組炎性因子水平顯著低于對(duì)照組（P<0.05）。經(jīng)治療，兩組前列腺液中C反應(yīng)蛋白（CRP）水平顯著降低，而白細(xì)胞介素-2（IL-2）、白細(xì)胞介素-4（IL-4）水平均顯著升高（P<0.05）；治療后，治療組前列腺液中炎癥指標(biāo)改善優(yōu)于對(duì)照組（P<0.05）。結(jié)論 清濁祛毒丸聯(lián)合環(huán)丙沙星治療慢性前列腺炎可促進(jìn)患者臨床癥狀改善，促進(jìn)患者性生活質(zhì)量改善，有利于降低機(jī)體炎癥因子水平，提高尿流率，有一定的臨床應(yīng)用價(jià)值。

Objective To investigate the effect of Qingzhuo Qudu Pills combined with ciprofloxacin in treatment of chronic prostatitis.Methods A total of 106 patients with chronic prostatitis who were treated in Zhengzhou First People's Hospital from July 2018 to August 2020 were selected, and all the patients were divided into control group (53 cases) and treatment group (53 cases) according to the odds-even number of hospitalization number. Patients in the control group were po administered with Ciprofloxacin Hydrochloride Tablets, 0.25 g/time, twice daily. Patients in the treatment group were po administered with Qingzhuo Qudu Pills on the basis of the control group, 8.0 g/time, three times daily. The two groups were compared after 4 weeks of treatment. The changes of related scores, urinary flow rate, serological indexes and prostatic fluid indexes were observed in two groups.Results After treatment, the total effective rate of the treatment group was 96.23%, which was significantly higher than that of the control group (81.13%,P<0.05). After treatment, NIH-CPSI scores in both groups were significantly decreased, but IIEF-5 scores and EQS scores were significantly increased (P<0.05). After treatment, the NIH-CPSI score in the treatment group was lower than that in the control group, but the IIEF-5 score and EQS score were higher than that in the control group (P<0.05). After treatment, the maximum urine flow rate (MFR) and average urine flow rate (AFR) in two groups were significantly increased (P<0.05). After treatment, MFR and AFR in treatment group were higher than those in control group (P<0.05). After treatment, serum interleukin-1β (IL-1β), interleukin-6 (IL-6), macrophage inflammatory protein-2 (MIP-2), tumor necrosis factor-α (TNF-α), and macrophage colony stimulating factor (M-CSF) were significantly decreased in two groups compared with before treatment (P<0.05). After treatment, the level of inflammatory factors in treatment group was significantly lower than that in control group (P<0.05). After treatment, the levels of C-reactive protein (CRP) in prostatic fluid of two groups were significantly decreased, but the levels of interleukin-2 (IL-2) and interleukin-4 (IL-4) were significantly increased (P<0.05). After treatment, the improvement of inflammatory indexes in prostatic fluid in treatment group was better than that in control group (P<0.05).Conclusion Qingzhuo Qudu Pills combined with ciprofloxacin can improve the clinical symptoms of patients in treatment of chronic prostatitis, and can improve the sexual life quality of patients, help to reduce the level of inflammatory factors in the body, improve the urinary flow rate, which has a certain clinical application value.

R983

河南省醫(yī)學(xué)科技攻關(guān)計(jì)劃項(xiàng)目（2018020731）